The role of IL-17 and family members in the pathogenesis of arthritis.
SourceCurrent Opinion in Investigational Drugs, 4, 5, (2003), pp. 572-7
Article / Letter to editor
Display more detailsDisplay less details
Current Opinion in Investigational Drugs
SubjectUMCN 1.4: Immunotherapy, gene therapy and transplantation; UMCN 4.2: Chronic inflammation and autoimmunity; UMCN 4.3: Tissue engineering and reconstructive surgery
Interleukin (IL)-17 is a T-cell-derived cytokine that is expressed in the synovium of patients with arthritis. IL-17 contributes to the pathogenesis of arthritis, and demonstrates additive or even synergistic effects with IL-1 and tumor necrosis factor (TNF) in inducing joint pathology. It is a potent inducer of receptor activator of nuclear factor-kappa B. IL-17 also has the capacity to induce joint destruction in an IL-1-independent manner. The discovery of IL-17 family members may further elucidate the role of this cytokine family in arthritis pathology, with IL-17F a promising candidate. Anti-IL-17 cytokine therapy may be an interesting new antirheumatic approach to the prevention of joint destruction, in addition to anti-TNF and anti-IL-1 therapy.
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.